Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 76, Issue 1, Pages 96-104
Publisher
BMJ
Online
2016-05-11
DOI
10.1136/annrheumdis-2015-209057
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
- (2015) Jasvinder A. Singh et al. Arthritis & Rheumatology
- Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
- (2014) Paul Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Early start and stop of biologics: has the time come?
- (2014) Ronald F van Vollenhoven et al. BMC Medicine
- Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis
- (2014) Paul Emery et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and
- (2012) Paul Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
- (2012) Jasvinder A. Singh et al. ARTHRITIS CARE & RESEARCH
- Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort
- (2012) Bin Zhang et al. ARTHRITIS RESEARCH & THERAPY
- American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
- (2011) D. T. Felson et al. ANNALS OF THE RHEUMATIC DISEASES
- The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy
- (2011) Paul Emery et al. ARTHRITIS AND RHEUMATISM
- Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
- (2010) M. Schoels et al. ANNALS OF THE RHEUMATIC DISEASES
- Treating rheumatoid arthritis to target: recommendations of an international task force
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) D. Aletaha et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
- (2008) J Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative
- (2008) K Visser et al. ANNALS OF THE RHEUMATIC DISEASES
- Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
- (2008) Edward Keystone et al. ARTHRITIS AND RHEUMATISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search